We used single-strand conformation polymorphism (SSCP) analysis of p53 exons 4 ± 8 to screen for possible mutations in 25 pediatric de novo leukemias with translocations of the MLL gene at chromosome band 11q23. Of the 25 patients, 21 were infants. Fifteen cases were acute myeloid leukemia (AML), eight were acute lymphoblastic leukemia (ALL), and two cases were biphenotypic. Nineteen cases were studied at diagnosis and six at time of relapse. p53 mutations were absent in all 19 cases studied at the time of diagnosis. The only mutation was a TGC?TTC transversion (cys?phe) at codon 141 in exon 5 in a case of infant ALL at relapse that occurred by subclone evolution after MLL gene translocation. We previously showed that p53 mutations are also absent in pediatric treatment-related leukemias with MLL gene translocations. The absence of p53 mutations at initial transformation may suggest that the anti-apoptotic eect of mutant p53 is not important in leukemias with MLL gene translocations. Alternatively, exogenous DNA damage may be the common feature in treatment-related and de novo cases. Since MLL gene translocations may occur through DNA repair and wildtype p53 is central to DNA repair, the absence of p53 mutations raises the possibility that wild-type p53, not mutant p53, may be important in the genesis of leukemias with these translocations.
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Keywords: p53; MLL; DNA topoisomerase II; DNA damage; translocation Translocations of the MLL gene at chromosome band 11q23 are the most common molecular abnormalities in acute leukemias of infants (Pui et al., 1995) . Epipodophyllotoxins and other DNA topoisomerase II inhibitors are associated with leukemias with similar translocations (Broeker et al., 1996; Felix et al., 1995a; Pedersen-Bjergaard et al., 1995; Pui et al., 1990; Winick et al., 1993) . Exposure to DNA damaging anticancer drugs, environmental toxins and DNA topoisomerase II inhibitors in foods may be the common epidemiologic feature in treatment-related and de novo cases Robison et al., 1989; Ross et al., 1996; Severson et al., 1993) . DNA topoisomerase II catalyzes transient cleavage and religation of both DNA strands of the double helix. Epipodophyllotoxins form a complex with the DNA and DNA topoisomerase II, decrease religation, and cause double-stranded chromosomal breakage (Corbett and Oshero, 1993) . The locations of the translocation breakpoints with respect to DNA topoisomerase II cleavage sites in MLL in de novo cases are consistent with a translocation mechanism involving chromosomal breakage by DNA topoisomerase II followed by resolution of DNA free ends through cellular mechanisms of DNA repair (Felix et al., 1995b) .
Wild-type p53 is a central molecule in DNA repair. DNA damage caused by certain exogenous mutagens including epipodophyllotoxins induces wild-type p53, a transcription factor that recognizes DNA damage, blocks cell cycle progression in late Gl, and mediates either apoptosis or DNA repair (Clarke et al., 1993; Kastan et al., 1991; Kuerbitz et al., 1992; Lowe et al., 1993; Maltzman and Czyzyk, 1984) . In addition, wildtype p53 has putative intrinsic 3'?5' exonuclease, DNA strand transferase and DNA strand annealing activities, which would be important in DNA repair (Bakalkin et al., 1994; Mummenbrauer et al., 1996; Oberosler et al., 1993) . We previously showed that p53 was wild-type in 14 of 14 treatment-related leukemias with MLL gene translocations (Felix et al., 1996) . In the present study we examined the frequency of p53 mutations in 25 de novo pediatric leukemias with MLL gene translocations because wildtype p53 is a central molecule in DNA repair and because DNA repair may play a role in the translocation mechanism.
The Institutional Review Board at the Children's Hospital of Philadelphia approved this research. Table  1 summarizes demographic, clinical, morphologic and cytogenetic features of the patients in this study. Of the 25 patients, 21 were infants. Fifteen cases were acute myeloid leukemia (AML), eight were acute lymphoblastic leukemia (ALL), and two cases were biphenotypic. Nineteen cases were examined at the time of diagnosis and six at time of relapse. Each leukemia showed MLL gene rearrangement at the level of the Southern blot (Table 1) (Felix et al., submitted) . Genomic DNAs extracted from leukemic marrow specimens were screened by SSCP analysis as previously described (Figure 1) (Felix et al., 1992b) . Table  2 summarizes the results of p53 mutation screening. p53 mutations were absent in p53 exon 4, exons 5 ± 6, exons 7 ± 8 and the¯anking introns in all 19 cases studied at the time of diagnosis and in ®ve of the six cases studied at relapse. SSCP analysis revealed a band shift pattern in the marrow of patient 38 with ALL that was typical of the polymorphism at p53 codon 213 in exon 6 (Figure 1 ) (Carbone et al., 1991) . PCR ampli®cation and direct sequencing of leukemia and parental genomic DNAs showed that the CGA?CGG polymorphism had been inherited from the mother.
The only observed mutation was in the ALL of patient 5, which was sampled at relapse. Consistent with replacement of the marrow by leukemic cells, the marrow aspirate was hypercellular with 89% abnormal blasts on dierential, the cytogenetic t(4;11) abnormality was present in each of 20 metaphases, and Southern blot analysis showed evidence of MLL gene rearrangement in the majority of cells (Table 1) (Felix et al., submitted) . SSCP analysis showed normal patterns for p53 exon 4 and exons 7 ± 8, and a predominantly normal pattern for exons 5 ± 6, with a less intense band shift pattern in the region of exon 5 (Figure 1 ). The mutation was not detected by direct sequencing of genomic DNA ± PCR products that encompassed the abnormal region, indicating that p53 was wild-type in the majority of cells. The predominantly normal SSCP migration pattern, less intense SSCP band shift and normal direct genomic sequence suggested subclone evolution because the relapse marrow largely was replaced by the abnormal blasts. To further evaluate this possibility, we ampli®ed fresh aliquots of marrow DNA by PCR and sequenced individual genomic subclones. Sequencing revealed the TGC?TTC transversion (cys?phe) at codon 141 in ®ve of 26 subclones from three separate PCR reactions. This mutation has not been described in leukemia before. These results suggest that p53 was wild-type in all 25 de novo cases at initial transformation and that the sole p53 mutation evolved sometime after MLL gene translocation.
The SSCP method is highly sensitive. For the conditions and primers utilized, serial dilution experiments demonstrated that one part mutant allele in 16 parts wild-type would be detected (Mitsudomi et al., 1992) . By comparisons with genomic sequencing, 92% of known p53 mutations resulted in abnormal patterns (Mitsudomi et al., 1992) . Thus, it is unlikely that mutations in the regions studied would be missed in specimens composed predominantly of leukemic cells, as was the case in the present study. We analysed p53 exons 4 ± 8 and the¯anking introns because the p53 mutations in leukemias that have been described occur within this region (Diccianni et al., 1994 , 1992a ,b, 1994 Greenblatt et al., 1994; Kawamura et al., 1995; Prokocimer and Rotter, 1994; Wada et al., 1993) . Thus, the data from this study would suggest that p53 mutations are infrequent in leukemias with MLL gene translocations. The lack of p53 mutations that we observed is similar to infrequent p53 mutations in leukemias with the t(1;19)(q23;p13) (Kawamura et al., 1995) . P]dCTP were ampli®ed from 100 ng genomic DNA. Oligonucleotide primers, conditions for PCR, digestion of PCR products with restriction enzymes, and conditions for resolution of the products in non-denaturing polyacrylamide gels were exactly as described (Mitsudomi et al., 1992) . Several specimens with the normal pattern for p53 exon 4, exons 5 ± 6, and exons 7 ± 8 are shown in 1a, 1b and 1c, respectively. Peripheral blood genomic DNAs from normal subjects were controls. Asterisk indicates common exon 4 polymorphism at codon 72, with both homozygous and heterozygous specimens included in the panel. Asterisk indicates pattern of the polymorphic allele at codon 213 in exon 6 in leukemic marrow of patient 38. Specimen of patient 5, sampled at time of relapse, showed predominantly normal pattern for exons 5 ± 6, with less intense band shift pattern (arrows), suggesting subclone evolution at p53 exon 5. p53 exons 5 ± 6 were ampli®ed from fresh aliquots of leukemia DNAs from patients 5 and 38 and peripheral blood lymphocyte DNAs from parents of patient 38 for direct automated sequencing. In the case of patient 5, products of three separate PCR reactions were also subcloned into pBluescript II SK + (Stratagene Inc., La Jolla, CA) for automated sequencing of individual genomic subclones. Direct sequencing showed codon 213 CGA?CGG polymorphism inherited from the mother in case of patient 38 (not shown). Direct sequence of marrow DNA of patient 5 was normal, but TGC?TTC transversion at codon 141 was detected in ®ve of 26 genomic subclones (not shown) p53 and MLL gene translocations MD Megonigal et al Studies on childhood ALL and AML alike all show that p53 mutations at initial diagnosis are present only in a few percent of cases. Wada et al. (1993) found that p53 mutations were absent in 27 cases of AML, primarily studied at the time of diagnosis. Combined studies in the literature indicate that p53 gene mutations are also rare in ALL, on the order of only 2% at initial presentation (Felix et al., 1992b; Kawamura et al., 1995; Wada et al., 1993) . In B-lineage ALL with the t(1;19) chromosomal translocation and in T-cell ALL, p53 mutations are acquired at relapse (Diccianni et al., 1994; Kawamura et al., 1995) . MDM2 gene overexpression without ampli®cation has been suggested as an alternative mechanism of wild-type p53 inactivation in childhood ALL, but karyotypes were not described (Marks et al., 1997; Zhou et al., 1995) . The status of the p53 gene in leukemias with other nonrandom translocations remains to be determined.
Where serial samples were available, we previously reported acquisition of a mutation at p53 codon 248 at relapse in a case of infant ALL with identical MLL gene rearrangements at both diagnosis and relapse (Felix et al., 1994 (Felix et al., , 1992b . Three recent studies also examined the frequency of p53 mutations in leukemias with MLL gene translocations (Cimino et al., 1997; Lanza et al., 1995 Lanza et al., , 1996 . Noteworthy in the series of Cimino et al. is the presence of complex karyotypes in two of ®ve cases with p53 mutations. The acquisition of yet additional (Felix et al., submitted) , where demographic, clinical and cytogenetic features and MLL gene rearrangements have been described and patient numbers were the same. All samples showed MLL gene rearrangement by Southern blot. Dx is diagnosis; Rel, relapse; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; FAB, the French American British classi®cation of morphology; nl, normal. p53 exons 4, 5 ± 6 and 7 ± 8 and¯anking introns were examined by SSCP analysis in all cases genetic changes besides MLL gene translocations and p53 mutation suggests that these specimens did not re¯ect the genotypes of initial transformation (Cimino et al., 1997) . Including cases in the present study, the de novo case with the codon 248 mutation acquired at relapse, the 14 treatment-related leukemias with MLL gene translocations where p53 was wild-type, and previous analyses of de novo cases, the p53 gene has been examined in a total of 84 leukemias with MLL gene translocations (Cimino et al., 1997; Felix et al., 1994 Felix et al., , 1996 Lanza et al., 1995 Lanza et al., , 1996 . p53 mutations were present in 16 of the 84 (19%). The presence of MLL gene translocations in all cases, the more limited p53 mutations, the proven acquisition of the p53 codon 248 mutation at relapse, and evidence in the present study for acquisition of the p53 codon 141 mutation by subclone evolution, may suggest a sequence of genetic changes where the p53 gene is wild-type at initial transformation, the translocation initiates leukemogenesis, and p53 mutations occur by clonal evolution. One interpretation of these data is that the anti-apoptotic eect of mutant p53 is unnecessary in the initiation of leukemias with such translocations.
Alternatively, the lack of p53 mutations raises the possibility that wild-type p53, not mutant p53, is more important in the genesis of leukemias with MLL gene translocations. The locations of de novo MLL genomic translocation breakpoints 5' of strong DNA topoisomerase II cleavage sites and untemplated bases at one translocation breakpoint junction have suggested a translocation mechanism involving chromosomal breakage by DNA topoisomerase II and resolution of DNA free ends through DNA repair (Felix et al., 1995b) . In particular, the requisite exonucleolytic processing of 3' DNA free ends left by DNA topoisomerase II and nucleotide insertion invoke DNA repair in the translocation mechanism. Wild-type p53 is central to DNA repair and has proven indirect and putative intrinsic DNA repair activities that could be of relevance in joining MLL with its translocation partners (Bakalkin et al., 1994; Lowe et al., 1993; Mummenbrauer et al., 1996; Oberosler et al., 1993) .
The requirement of cellular DNA repair machinery for formation of chromosomal translocations involving MLL, the proven DNA damage recognition function and indirect DNA repair activities of wild-type p53 as Figure 2 Proposed model for wild-type p53 involvement in MLL gene translocations. The location of de novo translocation breakpoints with respect to DNA topoisomerase II cleavage sites, and untemplated bases at the breakpoint junction suggest a translocation mechanism involving chromosomal breakage by DNA topoisomerase II, followed by resolution of DNA free ends from MLL and partner gene through DNA repair (Felix et al., 1995b) .VP/VM indicates epipodophyllotoxin anticancer drugs, which form a drug-stabilized intermediate with DNA and DNA topoisomerase II (Pommier and Bertrand, 1993) (top) . The interaction of a replication fork with the drug-stabilized intermediate can displace the DNA strands and cause breakage of the duplex DNA (Bodley et al., 1993; D'Arpa et al., 1990; Howard et al., 1994) (middle) . DNA damage then induces wild-type p53 (middle). p53 is wild-type in leukemias with translocations of the MLL gene. Since wild-type p53 has both indirect and putative intrinsic DNA repair activities, wild-type p53 may be one candidate participant, direct or indirect, in the resolution of DNA free ends that results in MLL gene translocations (bottom). The DNA repair involves 3'?5' exonucleolytic processing and nucleotide insertion before free ends of MLL and partner gene are joined (bottom). The model would accommodate disruption of DNA topoisomerase II activity by epipodophyllotoxin in treatment-related cases or by other DNA damage in de novo cases p53 and MLL gene translocations MD Megonigal et al a transcription factor, and the putative intrinsic DNA repair activities of wild-type p53 lead to the model shown in Figure 2 for the potential role of wild-type p53 in the formation of chromosomal translocations. The evidence would suggest that p53 generally is wildtype at initial transformation in leukemias with MLL gene translocations. Furthermore, epipodophyllotoxin DNA damage induces wild-type p53 (Kastan et al., 1991) . Since wild-type p53 is central to DNA repair, wild-type p53 may be one candidate participant, direct or indirect, in the repair of DNA free ends that results in MLL gene translocations.
